Joshi, M., Kim, S. E., Grivas, P., Wulff, E., Morgans, A. K., Mittal, K., Warrick, J., Reimers, M. A., Hahn, N. M., Haas, N. B., Wagner, L. I., Carducci, M. A. (2026). A phase III randomized trial of pembrolizumab in combination with sacituzumab govitecan vs standard of care in anti–PD-(L)1–resistant advanced urothelial cancer: ECOG-ACRIN EA8231.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.tps4641